Corcept Therapeutics Incorporated
DE ˙ DB ˙ US2183521028
63,24 € ↓ -0,74 (-1,16%)
2026-06-05
DEL PRIS
SecurityDE:HTD / Corcept Therapeutics Incorporated
InstitutionBridge City Capital, LLC
Latest Disclosed Ownership54,874 shares
Latest Disclosed Value $ 2,211,971
Bridge City Capital, LLC reports 85.79% increase in ownership of HTD / Corcept Therapeutics Incorporated

On May 13, 2026 - Bridge City Capital, LLC filed a 13F-HR form disclosing ownership of 54,874 shares of Corcept Therapeutics Incorporated (DE:HTD) valued at $1,892,604 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 29,535 shares of Corcept Therapeutics Incorporated. This represents a change in shares of 85.79% during the quarter. The current value of the position is $3,470,232 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F Corcept Therapeutics COM 218352102 54,874 25,339 85.79 2,212 115.29 0.6131
2026-02-13 2025-12-31 13F Corcept Therapeutics COM 218352102 29,535 10,324 53.74 1,028 -35.65 0.3021
2025-11-12 2025-09-30 13F Corcept Therapeutics COM 218352102 19,211 -331 -1.69 1,597 11.30 0.4263
2025-08-13 2025-06-30 13F Corcept Therapeutics COM 218352102 19,542 -22,487 -53.50 1,434 -70.12 0.4024
2025-04-14 2025-03-31 13F Corcept Therapeutics COM 218352102 42,029 -15,863 -27.40 4,801 64.55 1.4397
2025-02-11 2024-12-31 13F Corcept Therapeutics COM 218352102 57,892 518 0.90 2,917 9.87 0.7772
2024-11-14 2024-09-30 13F Corcept Therapeutics COM 218352102 57,374 8,137 16.53 2,655 66.04 0.7298
2024-08-13 2024-06-30 13F Corcept Therapeutics COM 218352102 49,237 -401 -0.81 1,600 27.92 0.5376
2024-04-12 2024-03-31 13F Corcept Therapeutics COM 218352102 49,638 386 0.78 1,250 -21.83 0.4554
2024-02-13 2023-12-31 13F Corcept Therapeutics COM 218352102 49,252 5,767 13.26 1,600 35.05 0.6198
2023-11-15 2023-09-30 13F Corcept Therapeutics COM 218352102 43,485 -17,147 -28.28 1,185 -12.23 0.5989
2023-08-16 2023-06-30 13F Corcept Therapeutics COM 218352102 60,632 35 0.06 1,349 2.82 0.6387
2023-05-15 2023-03-31 13F Corcept Therapeutics COM 218352102 60,597 -227 -0.37 1,313 131,100.00 0.6584
2023-01-25 2022-12-31 13F Corcept Therapeutics COM 218352102 60,824 -430 -0.70 1 -99.94 0.6337
2022-11-08 2022-09-30 13F Corcept Therapeutics COM 218352102 61,254 -22,564 -26.92 1,571 -21.17 0.8621
2022-08-15 2022-06-30 13F Corcept Therapeutics COM 218352102 83,818 -149 -0.18 1,993 5.39 1.0542
2022-05-18 2022-03-31 13F Corcept Therapeutics COM 218352102 83,967 -441 -0.52 1,891 13.17 0.8835
2022-01-20 2021-12-31 13F Corcept Therapeutics COM 218352102 84,408 -15 -0.02 1,671 0.60 0.6891
2021-11-10 2021-09-30 13F Corcept Therapeutics COM 218352102 84,423 -22,515 -21.05 1,661 -29.41 0.7534
2021-08-11 2021-06-30 13F Corcept Therapeutics COM 218352102 106,938 -3,574 -3.23 2,353 -10.50 0.8022
2021-04-28 2021-03-31 13F Corcept Therapeutics COM 218352102 110,512 -1,127 -1.01 2,629 -9.97 0.8714
2021-02-12 2020-12-31 13F Corcept Therapeutics COM 218352102 111,639 -1,159 -1.03 2,920 48.75 1.1082
2020-11-16 2020-09-30 13F Corcept Therapeutics COM 218352102 112,798 21,938 24.14 1,963 28.47 0.9373
2020-07-15 2020-06-30 13F Corcept Therapeutics COM 218352102 90,860 90,860 1,528 0.7010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.